Next Article in Journal
Overcoming Aminoglycoside Enzymatic Resistance: Design of Novel Antibiotics and Inhibitors
Next Article in Special Issue
Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents
Previous Article in Journal
MiR200 and miR302: Two Big Families Influencing Stem Cell Behavior
Previous Article in Special Issue
The Potential of Frog Skin-Derived Peptides for Development into Therapeutically-Valuable Immunomodulatory Agents
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Molecules 2018, 23(2), 283; https://doi.org/10.3390/molecules23020283

Peptides as Potential Therapeutics for Alzheimer’s Disease

Institute of Pathophysiology, Faculty of Medicine, Zaloška 4, SI-1000 Ljubljana, Slovenia
Received: 15 January 2018 / Revised: 26 January 2018 / Accepted: 28 January 2018 / Published: 30 January 2018
(This article belongs to the Special Issue Peptide Therapeutics)
Full-Text   |   PDF [605 KB, uploaded 30 January 2018]   |  

Abstract

Intracellular synthesis, folding, trafficking and degradation of proteins are controlled and integrated by proteostasis. The frequency of protein misfolding disorders in the human population, e.g., in Alzheimer’s disease (AD), is increasing due to the aging population. AD treatment options are limited to symptomatic interventions that at best slow-down disease progression. The key biochemical change in AD is the excessive accumulation of per-se non-toxic and soluble amyloid peptides (Aβ(1-37/44), in the intracellular and extracellular space, that alters proteostasis and triggers Aβ modification (e.g., by reactive oxygen species (ROS)) into toxic intermediate, misfolded soluble Aβ peptides, Aβ dimers and Aβ oligomers. The toxic intermediate Aβ products aggregate into progressively less toxic and less soluble protofibrils, fibrils and senile plaques. This review focuses on peptides that inhibit toxic Aβ oligomerization, Aβ aggregation into fibrils, or stabilize Aβ peptides in non-toxic oligomers, and discusses their potential for AD treatment. View Full-Text
Keywords: aggregation; Alzheimer’s disease; amyloid β oligomers; amyloid β peptide; amyloid β plaques; insulin; neurofibrillary tangles; tau protein; peptides; peptide therapy aggregation; Alzheimer’s disease; amyloid β oligomers; amyloid β peptide; amyloid β plaques; insulin; neurofibrillary tangles; tau protein; peptides; peptide therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Ribarič, S. Peptides as Potential Therapeutics for Alzheimer’s Disease. Molecules 2018, 23, 283.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top